Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00044707 · ClinicalTrials.gov registry record · Phase 2

Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide

A Phase 2 study, sponsored by AstraZeneca.

Completed
Registry status
Phase 2
Development phase
24
Enrollment target

NCT00044707 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 24 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00044707, a Phase 2 study, has completed, sponsored by AstraZeneca.

COMPLETED
Registry status
Phase 2
Development phase
24 participants
Enrollment target

Study Summary

This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect of pramlintide on the pharmacokinetics of an orally administered medication

Interventions

  • DRUG Pramlintide acetate

Trial Details

FieldValue
Enrollment Target 24 participants
Start Date 2002-08
Est. Completion 2002-09
Phase Phase 2

Sponsor

AstraZeneca

1,285 total trials

What the Registry Record Tells You About NCT00044707

The ClinicalTrials.gov registry entry for NCT00044707 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 24 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Pramlintide acetate is the first listed.

NCT00044707 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT00044707 about?

NCT00044707 is a clinical study titled "Evaluation of an Orally Administered Medication When Taken in Conjunction With Pramlintide". This is a randomized, single-blind, placebo-controlled, crossover study to examine the effect of pramlintide on the pharmacokinetics of an orally administered medication

What is the current status of trial NCT00044707?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 24 participants. The study started on 2002-08. Estimated completion is 2002-09.

What interventions are being tested in trial NCT00044707?

The interventions under investigation include: Pramlintide acetate (DRUG).

Who is sponsoring clinical trial NCT00044707?

This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.